Phase 1/2 Study Of Sel24/Men1703, A First-In-Class Dual Pim/Flt3 Kinase Inhibitor, In Patients With Idh1/2-Mutated Acute Myeloid Leukemia: The Diamond-01 Trial.
MEN-1703
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase 1/2 Study Of Sel24/Men1703, A First-In-Class Dual Pim/Flt3 Kinase Inhibitor, In Patients With Idh1/2-Mutated Acute Myeloid Leukemia: The Diamond-01 Trial. ### Output: MEN-1703